U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06861270) titled 'Estimation of Non-Reimbursable Costs for Patients With Duchenne Muscular Dystrophy in France' on Sept. 25, 2024.
Brief Summary: Duchenne muscular dystrophy (DMD) is a chronic neuromuscular disorder affecting approximately 150 to 200 newborns annually, predominantly males, and is characterized by progressive muscle atrophy and weakness due to a complete absence of dystrophin. DMD presents a severe phenotype, with life expectancy typically extending into the third decade. Data on healthcare utilization and associated costs for DMD patients, particularly within the French healthcare context, remain limited. The EPARDYS study aims to ex...